Answers are grounded in this paper and cite their sources.
Despite significant progress, metastatic urothelial cancer remains an incurable condition with a limited life expectancy. Platinum-based chemotherapy is still the mainstay of treatment for metastatic disease, but immunotherapy, antibody drug conjugates, and targeted agents have shown encouraging results in several recent practice changing trials. In this review, we discuss the standard of care, recent therapeutic advances, ongoing clinical trials, and future perspectives in metastatic urothelial carcinoma.
No takes yet. Share an insight, caveat, or question.
Stecca et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: